17 July 2025

16 July 2025

16 July 2025

Trump tariffs

Trump says pharmaceutical tariffs could reach 200%

US president threatens levies on drugmakers after 'a certain period of time'

Pharmaceuticals

Rakuten Medical teams on light-based cancer treatment with Taiwan company

California startup recruits partner OEP for photoimmunotherapy in Asian markets

Pharmaceuticals

Novo Nordisk launches Wegovy in India as weight-loss market heats up

Early release comes months after rival Eli Lilly began offering its own drug

Business deals

German drugmaker Boehringer eyes Japan as Asia hub with $346m investment

Production of key diabetes treatment aims to meet growing demand across region

Pharmaceuticals

Japan drugmaker Chugai invests in Western startups

Company's venture capital arm on hunt for promising technologies and candidates

Bonds

Takeda's downsized bond offering reveals new investor caution

Japan drugmaker missed goal in recent issuance, despite high-quality debt

Pharmaceuticals

Takeda CEO Christophe Weber faces opposition to board reelection

Proxy adviser ISS also calls for voting down proposed bonuses for directors

Pharmaceuticals

Drugmaker Roche's global investments crucial to cutting costs: CEO

Subsidiary Chugai's autonomy helps Japan firm innovate, Schinecker says

Pharmaceuticals

Biogen, Eisai to shift some Alzheimer's drug production to US

Eli Lilly, other drugmakers eye similar plans as Trump tariff countermeasure

Pharmaceuticals

Takeda Pharmaceutical to invest $30bn in US over 5 years: CEO

Trump's potential pharma tariffs prompt drugmakers to devise spending plans

Business deals

Japanese drugmaker Shionogi to acquire JT's pharma units in $1.1bn deal

Tobacco company to exit drug business amid industry restructuring and high research costs

Pharmaceuticals

Biogen partner Eisai cut US jobs. Now can it boost Alzheimer's drug sales?

Japanese drugmaker aims for faster, easier adoption of Leqembi

Pharmaceuticals

US, Japan drugmakers target ALS-causing genes with new therapies

Biogen, Otsuka and others find novel ways to fight debilitating disease

Pharmaceuticals

Japan's Fujifilm rides US-China rift to land $3bn biopharma deal

Policy to expand domestic medicine production will drive rapid growth

Pharmaceuticals

Japan drug companies offer rare haven amid Trump market jitters

Most big-cap stocks make year-to-date gains even as 25% tariff looms

Pharmaceuticals

Eli Lilly releases Zepbound obesity drug in Japan, targeting 'hidden' fat

Pharmaceutical company eyes 18m potential patients and sales of $224m at peak

Pharmaceuticals

Japan stem cell researchers claim success in Parkinson's treatment

Therapy said to grow healthy nerve cells to improve patients' motor function

Pharmaceuticals

India's generic drug industry feels pressure of Trump tariff threat

Pharma giants like Bayer, Takeda also weigh supply chain risks

Business deals

Sumitomo teams with U.S. fusion startup on cancer treatments

Japan trading house's ties with Shine include energy development

Markets

Immune to Trump tariffs, Japan rail stocks defy market plunge

Sectors supported by domestic demand outperform amid trade war worries

Business deals

Japan's Marubeni to buy Sumitomo Pharma's Asia business for $300m

Trading house has drug sales operations in Africa and Middle East

Health Care

Fosun Pharma to sell $124m stake in hospital chain to Warburg Pincus

Deal with U.S. fund lets Chinese company focus on drug development

Pharmaceuticals

Novartis sees radioactive cancer drugs becoming $10bn business: CEO

Company to also focus on areas it can innovate in over crowded anti-obesity market

Pharmaceuticals

Taiwan biopharmaceutical startup takes page from TSMC's playbook

TBMC emulates chipmaker in more than name, aiming to shield home island from risk

Pharmaceuticals

Alzheimer's treatment maker Eisai's shares sink on slow U.S. sales

Biogen partner struggles to increase Leqembi recipients amid lack of facilities

Pharmaceuticals

Novartis to mass produce next-generation cancer drugs in Japan

Swiss drugmaker plans to start making radiopharmaceuticals there in 2026